Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

(2023) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

(2023) Y. Kubota et al.   ESMO Open

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

(2022) Yoon-Koo Kang et al.   LANCET ONCOLOGY

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

(2022) Kohei Shitara et al.   NATURE

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2022) F. Lordick et al.   ANNALS OF ONCOLOGY

Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)

(2022)   Gastric Cancer

FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma

(2021) U. Sahin et al.   ANNALS OF ONCOLOGY

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

(2021) Feng‐Hua Wang et al.   Cancer Communications

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas

(2021) Antonio Pellino et al.   Journal of Personalized Medicine

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry

(2020) Florian Huemer et al.   Journal of Clinical Medicine

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

(2020) Theo Vos et al.   LANCET

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

(2019) Charles S Fuchs et al.   LANCET ONCOLOGY

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

(2019) O Türeci et al.   ANNALS OF ONCOLOGY

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

(2018) Ugur Sahin et al.   EUROPEAN JOURNAL OF CANCER

103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples

(2018) D Moran et al.   ANNALS OF ONCOLOGY

Targeted therapies for gastric cancer: failures and hopes from clinical trials

(2017) Maria Apicella et al.   Oncotarget

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

Tight junction-related human diseases

(2013) Norimasa Sawada   PATHOLOGY INTERNATIONAL

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development

(2008) U. Sahin et al.   CLINICAL CANCER RESEARCH